Arterra Bioscience Spa · MIL:ARBS
Arterra Bioscience Spa — NEXT GEMs Micro Cap Conference (November 2020)
14 slides from Arterra Bioscience Spa's conference presentation, November 2020
Slide 1: GEMs Presentation
GEMs PRESENTATION Milan, November 2020 Strictly Private & Confidential 1
Slide 2: Mission
Mission • Arterra Bioscience is an Italian research-based biotech company («PMI Innovativa») with a strong know-how in biological science and an extensive experience in screening for the discovery of active molecules. • By studying signal transduction mechanisms in plants, animals and human cells, A
Slide 3: Biotech and its potential
Biotech and its potential BIOTECHNOLOGY BLUE GREEN WHITE RED FOR THE BIOTECH BIOTECH BIOTECH BIOTECH RESEARCH AND THE marine and agricultural raw materials gene to DEVELOPMENT OF fresh water processes and to valuable drug NEW ACTIVE organisms plants products discovery COMPOUNDS TESTING DISCOVERY PLA
Slide 4: Shareholders & Board Members
Shareholders & Board Members Main shareholders Industrial shareholders Other shareholders Other Gabriella Colucci Paolo Colucci Floating shares shareholders <5% 28.4% 7.6% 26.9% 4.6% 16.8% 8.8% Maarten Chrispeels 6.9% BOARD OF DIRECTORS Dr. Gabriella Dr. Fabio Gualtiero Ioimo Colucci Apone CFO (inte
Slide 5: The Research Process is the initial stage of the business value chain
The Research Process is the initial stage of the business value chain Research Grants Research Contracts Scientific Breakthrough New Technology Market needs RESEARCH IDEA INTERNAL SCIENTIFIC AGRIFOOD COSMETICS COMMITTEE AGRICULTURE NUTRACEUTICAL NUTRACEUTICAL Production MEDICAL DEVICES Licence IP &
Slide 6: Commercialization of active ingredients in the Cosmetic industry
Commercialization of active ingredients in the Cosmetic industry SMALL VOLUMES BIG MARGINS Arterra commercializes active ingredients for the Cosmetic industry through two different channels, which interact directly with renowned global brands: A • Vitalab, a joint venture with Intercos, which repres
Slide 7: Key Investment Highlights
Key Investment Highlights Bioscience great momentum since environmental 1 sustainability is becoming crucial for a huge number of industries Biotech company with an outstanding 2 R&D and highly qualified Technology Team A global reach and presence with low 3 commercial investments Huge potential in
Slide 8: Limited production costs driving compelling profitability
Limited production costs driving compelling profitability: thriving upside arising from additional revenues to be mostly converted in EBITDA Turnover (€/000) Ebitda (€/000) Net Income (€/000) 3.626 2.978 119 34,1% 2.745 42,5% 38,3% 35,1% 799 56 27,1% 23,6% 556 636 1.167 1.236 2.709 1.140 2.427 1.044
Slide 9: First semester of 2020 results
The first semester of 2020 has shown a slight increase in revenues, while the marginality has declined due to investments in equipment and staff Turnover (€/000) EBIT & EBITDA (€/000) Net Income (€/000) 2.074 = % margin on VdP = % margin on VdP 1.872 75 1.340 374 492 39,6% 37,0% 29,7% 33,5% 333 33,0
Slide 10: Cosmetic growth with and beyond Intercos
Cosmetic growth with and beyond Intercos • Sales growth in Global Prestige Markets • Sales growth in the new Independent Green Brands • Sales growth in make-up market • Expansion in new countries (India, Malaysia, Thailand, Japan, Brazil) • New multinational clients through Vitalab Sales Via Vitalab
Slide 11: Diversification Phase
Diversification Phase • The developed technological platforms are suitable or adaptable for the identification of active molecules effective as medical devices, food supplements, natural food preservatives, bio-agricultural solutions or plant bio stimulants. Arterra is developing several projects in
Slide 12: Use of Proceeds
Use of Proceeds • Strengthening of the Business Development division to better reach new industries (Medical Devices, Nutraceutical, etc.). Arterra aims at adopting smarter technological techniques of INNOVATION production, in order to avoid the risk of a human error in the production phase • Streng
Slide 13: Main achievements in 2019-2020
Main achievements in 2019-2020 IPO • Listing on AIM Italia on October 28th, 2019 • Hired the COO (chemical engineer with consolidated experience in important ORGANISATION industrial groups) • Hired a new qualified scientist in order to develop innovative natural molecules for multi-applications • 9-
Slide 14: A successful IPO
A successful IPO Number of shares 6.544.580 Free Float 26,9% Market Cap ~ 24,2M Shares issued 2.208.000 New issue 1.536.000 Selling shares 384.000 Greenshoe 288.000 Warrants* (1: 4 shares) 552.000 Strike price (IPO Price+10%) € 2,86 1st exercise period (28 days) October 2020 IPO Shares Price € 2,6 I
Arterra Bioscience — NEXT GEMs Micro Cap Conference (November 2020) on 6ix